Advertisement

Molecular Medicine

, Volume 15, Issue 1–2, pp 1–10 | Cite as

Macrophage Migration Inhibitory Factor Promotes Colorectal Cancer

  • Xing-Xiang He
  • Ken Chen
  • Jun Yang
  • Xiao-Yu Li
  • Huo-Ye Gan
  • Cheng-Yong Liu
  • Thomas R. Coleman
  • Yousef Al-Abed
Research Article

Abstract

A growing body of evidence implicates macrophage migration inhibitory factor (MIF) in tumorigenesis and metastasis. In this study, we investigated whether MIF expression was associated with clinicopathologic features of colorectal carcinoma (CRC), especially in tumors with hepatic metastasis, and whether neutralization of endogenous MIF using anti-MIF therapeutics would inhibit tumor growth and/or decrease the frequency of colorectal hepatic metastases in a mouse colon carcinoma model. The concentration of serum MIF was positively correlated with an increased risk of hepatic metastasis in human patients with CRC (R = 1.25, 95% confidence internal = 1.02–1.52, P = 0.03). MIF was also dramatically upregulated in human colorectal tissue, with 20–40 times as many MIF-positive cells found in the mucosa of patients with CRC than in normal tissue (P < 0.001 ANOVA). Moreover, in those patients with metastatic colorectal cancer in the liver, MIF-positive cells were similarly increased in the diseased hepatic tissue. This increased MIF expression was restricted to diseased tissue and not found in areas of the liver with normal morphology. In subsequent in vitro experiments, we found that addition of recombinant MIF to colonic cell lines significantly increased their invasive properties and the expression of several genes (for example, matrix metalloproteinase 9 and vascular endothelial growth factor) known to be upregulated in cancerous tissue. Finally, we treated mice that had been given CT26 colon carcinoma cell transplants with anti-MIF therapeutics—either the MIF-specific inhibitor ISO-1 or neutralizing anti-MIF antibodies—and observed a significant reduction in tumor burden relative to vehicle-treated animals. Taken together, these data demonstrate that MIF expression was not only correlated with the presence of colorectal cancer but also may play a direct role in cancer development.

Notes

Acknowledgments

This project was supported by the National Natural Science Foundation of China (NSFC) (30470435), the Provincial Natural Science Foundation of Guangdong (06022450 and 710173), the Provincial Science and technology Grant of Guangdong (2008A030201001), and the Science and technology Grant of Zhongshan Science & Technology Bureau (20073A185) to Dr. XingXiang He. We appreciate the support of Yiwen Deng and Chuyuan Hong in the Department of Gastroenterosurgery in collecting the colorectal carcinoma specimens. We thank Hang Su in the Clinical Laboratory Center of Molecular Medicine and Degui Liao in the Department of Pathology for technical assistance.

References

  1. 1.
    Boyle P, Ferlay J. (2005) Cancer incidence and mortality in Europe, 2004. Ann.Oncol 16:481–488.CrossRefGoogle Scholar
  2. 2.
    American Cancer Society. (2006) Cancer facts and figures, 2005. Atlanta, GA: American Cancer Society.Google Scholar
  3. 3.
    Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. (2002) Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect. 4:449–460.CrossRefGoogle Scholar
  4. 4.
    Mitchell RA, et al. (2002) Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. U. S. A. 99:345–350.CrossRefGoogle Scholar
  5. 5.
    White ES, et al. (2003) Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin. Cancer Res. 9:853–860.PubMedGoogle Scholar
  6. 6.
    Takahashi N, et al. (1998) Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol. Med. 4:707–714.CrossRefGoogle Scholar
  7. 7.
    Chesney J, et al. (1999) An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. 5:181–191.CrossRefGoogle Scholar
  8. 8.
    Yang Y, Degranpre P, Kharfi A, Akoum A. (2000) Identification of macrophage migration inhibitory factor as a potent endothelial cell growth-promoting agent released by ectopic human endometrial cells. J. Clin. Endocrinol. Metab 85:4721–4727.PubMedGoogle Scholar
  9. 9.
    Ogawa H, et al. (2000) An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine 12:309–314.CrossRefGoogle Scholar
  10. 10.
    Sun B, et al. (2005) Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res. 11:1050–1058.PubMedGoogle Scholar
  11. 11.
    Hudson JD, et al. (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190:1375–1382.CrossRefGoogle Scholar
  12. 12.
    Meyer-Siegler K, Hudson PB. (1996) Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 48:448–452.CrossRefGoogle Scholar
  13. 13.
    Bini L, et al. (1997) Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18:2832–2841.CrossRefGoogle Scholar
  14. 14.
    Ren Y, et al. (2003) Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int. J. Cancer 107:22–29.CrossRefGoogle Scholar
  15. 15.
    Kamimura A, et al. (2000) Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 89:334–341.CrossRefGoogle Scholar
  16. 16.
    Ren Y, et al. (2005) Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg 242:55–63.CrossRefGoogle Scholar
  17. 17.
    Li Z, et al. (2004) Macrophage migration inhibitory factor enhances neoplastic cell invasion by inducing the expression of matrix metalloproteinase 9 and interleukin-8 in nasopharyngeal carcinoma cell lines. Chin Med. J. (Engl.) 117:107–114.Google Scholar
  18. 18.
    Dios A, et al. (2002) Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J. Med. Chem. 45:2410–2416.CrossRefGoogle Scholar
  19. 19.
    Al-Abed Y, et al. (2005) ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J. Biol. Chem. 280:36541–36544.CrossRefGoogle Scholar
  20. 20.
    Lubetsky JB, et al. (2002) The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277:24976–24982.CrossRefGoogle Scholar
  21. 21.
    Cvetkovic I, et al. (2005) Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 146:2942–2951.CrossRefGoogle Scholar
  22. 22.
    Nemajerova A, Moll UM, Petrenko O, Fingerle-Rowson G. (2007) Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle. Cell Cycle (Georgetown, Tex.) 6:1030–1034.CrossRefGoogle Scholar
  23. 23.
    Ohkawara T, et al. (2005) Transgenic over-expression of macrophage migration inhibitory factor renders mice markedly more susceptible to experimental colitis. Clin. Exp. Immunol. 140:241–248.CrossRefGoogle Scholar
  24. 24.
    Nicoletti F, et al. (2005) Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barre syndrome and experimental allergic neuritis. J. Neuroimmunol. 168:168–174.CrossRefGoogle Scholar
  25. 25.
    Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. (2006) Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J. Immunol. 177:8730–8739.CrossRefGoogle Scholar
  26. 26.
    Rendon BE, et al. (2007) Regulation of human lung adenocarcinoma cell migration and invasion by MIF. J Biol. Chem. 282:29910–29918.CrossRefGoogle Scholar
  27. 27.
    Sakuragi T, et al. (2007) Lung-derived macrophage migration inhibitory factor in sepsis induces cardio-circulatory depression. Surg. Infect. (Larchmt) 8:29–40.CrossRefGoogle Scholar
  28. 28.
    Calandra T, Roger T. (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 3:791–800.CrossRefGoogle Scholar
  29. 29.
    Flaster H, Bernhagen J, Calandra T, Bucala R. (2007) The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol. Endocrinol. 21:1267–1280.CrossRefGoogle Scholar
  30. 30.
    Shun CT, Lin JT, Huang SP, Lin MT, Wu MS. (2005) Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas. World J. Gastroenterol. 11:3767–3771.CrossRefGoogle Scholar
  31. 31.
    Sun B, et al. (2003) Induction of macrophage migration inhibitory factor by lysophosphatidic acid: relevance to tumor growth and angiogenesis. Int. J. Mol. Med. 12:633–641.PubMedGoogle Scholar
  32. 32.
    Wilson JM, et al. (2005) Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129:1485–1503.CrossRefGoogle Scholar
  33. 33.
    Werner JA, Rathcke IO, Mandic R. (2002) The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin. Exp. Metastasis 19:275–282.CrossRefGoogle Scholar
  34. 34.
    Zeng ZS, Cohen AM, Guillem JG. (1999) Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 20:749–755.CrossRefGoogle Scholar
  35. 35.
    Heslin MJ, et al. (2001) Role of matrix metalloproteinases in colorectal carcinogenesis. Ann. Surg. 233:786–792.CrossRefGoogle Scholar
  36. 36.
    Moran A, et al. (2005) Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol. Rep. 13:115–120.PubMedGoogle Scholar
  37. 37.
    Li BH, et al. (2005) Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. World J. Gastroenterol. 11:3046–3050.CrossRefGoogle Scholar
  38. 38.
    Curran S, et al. (2004) Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin. Cancer Res. 10:8229–8234.CrossRefGoogle Scholar
  39. 39.
    Ogata Y, et al. (2006) The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother. Pharmacol. 57:577–583.CrossRefGoogle Scholar
  40. 40.
    Chen X, et al. (2005) Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells. Int. J. Cancer 116:52–61.CrossRefGoogle Scholar
  41. 41.
    Meyer E, Vollmer JY, Bovey R, Stamenkovic I. (2005) Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Cancer Res. 65:4261–4272.CrossRefGoogle Scholar
  42. 42.
    Hagemann T, et al. (2005) Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J. Immunol. 175:1197–1205.CrossRefGoogle Scholar
  43. 43.
    Onodera S, et al. (2002) Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts: relevance to intracellular signaling pathways. J. Biol. Chem. 277:7865–7874.CrossRefGoogle Scholar
  44. 44.
    Plate KH, Breier G, Weich HA, Risau W. (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848.CrossRefGoogle Scholar
  45. 45.
    Nakasaki T, et al. (2002) Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am. J. Hematol. 69:247–254.CrossRefGoogle Scholar
  46. 46.
    Kondo Y, et al. (2000) Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma. Cancer 88:1820–1827.CrossRefGoogle Scholar
  47. 47.
    Nanashima A, et al. (1998) Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers. Dig. Dis. Sci. 43:2634–2640.CrossRefGoogle Scholar
  48. 48.
    Kondo Y, et al. (2000) Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line. Clin. Cancer Res. 6:622–630.PubMedGoogle Scholar
  49. 49.
    Ishigami SI, et al. (1998) Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer 78:1379–1384.CrossRefGoogle Scholar
  50. 50.
    Landriscina M, et al. (1998) Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br. J. Cancer 78:765–770.CrossRefGoogle Scholar
  51. 51.
    Kumar H, et al. (1998) Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin. Cancer Res. 4:1279–1285.PubMedGoogle Scholar
  52. 52.
    Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K. (1998) Circulating vascular endothelial growth factor in patients with colorectal cancer. Am. J. Gastroenterol. 93:249–252.CrossRefGoogle Scholar
  53. 53.
    Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G, et al. (2008) Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res. 68:285–91.CrossRefGoogle Scholar
  54. 54.
    Zaman K, et al. (2006) Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int. J. Cancer 118:755–764.CrossRefGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2009

Authors and Affiliations

  • Xing-Xiang He
    • 1
  • Ken Chen
    • 1
  • Jun Yang
    • 2
  • Xiao-Yu Li
    • 3
  • Huo-Ye Gan
    • 3
  • Cheng-Yong Liu
    • 3
  • Thomas R. Coleman
    • 4
  • Yousef Al-Abed
    • 4
    • 5
  1. 1.Department of GastroenterologyThe First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuangzhou, GuangdongChina
  2. 2.Department of EpidemiologyRoswell Park Cancer InstituteBuffaloUSA
  3. 3.Department of GastroenterologyThe Second Affiliated Hospital of Guangzhou Medical CollegeGuangzhou, GuangdongChina
  4. 4.Laboratory of Medicinal ChemistryThe Feinstein Institute for Medical ResearchManhassetUSA
  5. 5.New York University School of MedicineNew YorkUSA

Personalised recommendations